UNLABELLED: In vivo estimation of β(2)-nicotinic acetylcholine receptor availability with molecular neuroimaging is complicated by competition between the endogenous neurotransmitter acetylcholine and the radioligand (123)I-3-[2(S)-2-azetidinylmethoxy]pyridine ((123)I-5-IA). We examined whether binding of (123)I-5-IA is sensitive to increases in extracellular levels of acetylcholine in humans, as suggested in nonhuman primates. METHODS: Six healthy subjects (31 ± 4 y) participated in a (123)I-5-IA SPECT study. After baseline scans, physostigmine (1-1.5 mg) was administered intravenously over 60 min, and 9 additional scans were obtained. RESULTS: We observed a significant reduction in the total volume of distribution after physostigmine administration (29% ± 17% in the cortex, 19% ± 15% in the thalamus, 19% ± 15% in the striatum, and 36% ± 30% in the cerebellum; P < 0.05). This reduction reflected a combination of a region-specific 7%-16% decrease in tissue concentration of tracer and a 9% increase in plasma parent concentration. CONCLUSION: These data suggest that increases in acetylcholine compete with (123)I-5-IA for binding to β(2)-nicotinic acetylcholine receptor. Additional validation of this paradigm is warranted, but it may be used to interrogate changes in extracellular acetylcholine.
UNLABELLED: In vivo estimation of β(2)-nicotinic acetylcholine receptor availability with molecular neuroimaging is complicated by competition between the endogenous neurotransmitter acetylcholine and the radioligand (123)I-3-[2(S)-2-azetidinylmethoxy]pyridine ((123)I-5-IA). We examined whether binding of (123)I-5-IA is sensitive to increases in extracellular levels of acetylcholine in humans, as suggested in nonhuman primates. METHODS: Six healthy subjects (31 ± 4 y) participated in a (123)I-5-IA SPECT study. After baseline scans, physostigmine (1-1.5 mg) was administered intravenously over 60 min, and 9 additional scans were obtained. RESULTS: We observed a significant reduction in the total volume of distribution after physostigmine administration (29% ± 17% in the cortex, 19% ± 15% in the thalamus, 19% ± 15% in the striatum, and 36% ± 30% in the cerebellum; P < 0.05). This reduction reflected a combination of a region-specific 7%-16% decrease in tissue concentration of tracer and a 9% increase in plasma parent concentration. CONCLUSION: These data suggest that increases in acetylcholine compete with (123)I-5-IA for binding to β(2)-nicotinic acetylcholine receptor. Additional validation of this paradigm is warranted, but it may be used to interrogate changes in extracellular acetylcholine.
Authors: Julie K Staley; Christopher H van Dyck; David Weinzimmer; Eric Brenner; Ronald M Baldwin; Gilles D Tamagnan; Patrizia Riccardi; Effie Mitsis; John P Seibyl Journal: J Nucl Med Date: 2005-09 Impact factor: 10.057
Authors: S I Chefer; A G Horti; K S Lee; A O Koren; D W Jones; J G Gorey; J M Links; A G Mukhin; D R Weinberger; E D London Journal: Life Sci Date: 1998 Impact factor: 5.037
Authors: Masahiro Fujita; John P Seibyl; D Bruce Vaupel; Gilles Tamagnan; Michele Early; Sami S Zoghbi; Ronald M Baldwin; Andrew G Horti; Andrei O KoreN; Alexey G Mukhin; Shaukat Khan; Ali Bozkurt; Alane S Kimes; Edythe D London; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2002-02 Impact factor: 9.236
Authors: Masahiro Fujita; Mohammed S Al-Tikriti; Gilles Tamagnan; Sami S Zoghbi; Ali Bozkurt; Ronald M Baldwin; Robert B Innis Journal: Synapse Date: 2003-06-01 Impact factor: 2.562
Authors: J R Ellis; V L Villemagne; P J Nathan; R S Mulligan; S J Gong; J G Chan; J Sachinidis; G J O'Keefe; K Pathmaraj; K A Wesnes; G Savage; C C Rowe Journal: Neurobiol Learn Mem Date: 2008-07-11 Impact factor: 2.877
Authors: Arthur L Brody; Mark A Mandelkern; Matthew R Costello; Anna L Abrams; David Scheibal; Judah Farahi; Edythe D London; Richard E Olmstead; Jed E Rose; Alexey G Mukhin Journal: Int J Neuropsychopharmacol Date: 2008-08-18 Impact factor: 5.176
Authors: Irina Esterlis; Effie M Mitsis; Jeffery C Batis; Frederic Bois; Marina R Picciotto; Stephanie M Stiklus; Tracy Kloczynski; Edward Perry; John P Seibyl; Sherry McKee; Julie K Staley; Kelly P Cosgrove Journal: Int J Neuropsychopharmacol Date: 2010-10-29 Impact factor: 5.176
Authors: Christine DeLorenzo; Nicole DellaGioia; Michael Bloch; Gerard Sanacora; Nabeel Nabulsi; Chadi Abdallah; Jie Yang; Ruofeng Wen; J John Mann; John H Krystal; Ramin V Parsey; Richard E Carson; Irina Esterlis Journal: Biol Psychiatry Date: 2014-07-10 Impact factor: 13.382
Authors: Yann S Mineur; Matthew P Bentham; Wen-Liang Zhou; Margreet E Plantenga; Sherry A McKee; Marina R Picciotto Journal: Psychopharmacology (Berl) Date: 2015-07-07 Impact factor: 4.530
Authors: Jonas O Hannestad; Kelly P Cosgrove; Nicole F DellaGioia; Evgenia Perkins; Frederic Bois; Zubin Bhagwagar; John P Seibyl; Tristan D McClure-Begley; Marina R Picciotto; Irina Esterlis Journal: Biol Psychiatry Date: 2013-06-14 Impact factor: 13.382
Authors: Irina Esterlis; Ansel T Hillmer; Frederic Bois; Brian Pittman; Erin McGovern; Stephanie S O'Malley; Marina R Picciotto; Bao-Zhu Yang; Joel Gelernter; Kelly P Cosgrove Journal: Nicotine Tob Res Date: 2016-03-31 Impact factor: 4.244
Authors: Ansel T Hillmer; Dustin W Wooten; Mohammed Farhoud; Andrew T Higgins; Patrick J Lao; Todd E Barnhart; Jogeshwar Mukherjee; Bradley T Christian Journal: Synapse Date: 2013-08-30 Impact factor: 2.562